Source: Fortune Business Insights
The global gene therapy market is on a robust growth trajectory, driven by rising prevalence of genetic disorders, rapid technological advancements, and increasing regulatory approvals. Gene therapy works by introducing, altering, or replacing genetic material within a patient's cells to treat or prevent disease — offering a potentially curative approach where conventional treatments fall short. Conditions such as spinal muscular atrophy, hemophilia, sickle cell disease, and inherited retinal diseases are among the primary targets driving market momentum.
The single most significant driver is the growing global burden of genetic and rare diseases. The World Federation of Hemophilia reported over 218,000 patients with hemophilia in 2023 alone, underscoring the scale of unmet medical need. Simultaneously, surging R&D investments and funding — such as SpliceBio's Series B funding of USD 127.7 million in June 2025 — are accelerating pipeline development. Expanding regulatory support, particularly rapid FDA approvals in North America, is also fast-tracking market access for novel therapies.
Despite promising growth, the market faces significant headwinds. The most pressing restraint is the prohibitively high cost of gene therapies. For instance, CSL's hemophilia B gene therapy carries a one-time treatment cost of USD 3.5 million, creating formidable financial barriers for patients and healthcare systems. Another key challenge is maintaining long-term clinical efficacy. Transgene expression tends to decline over time due to immune responses or promoter silencing, raising concerns about durability — an issue that led the U.S. FDA to reject BioMarin's hemophilia A therapy in 2020 due to insufficient durability data.
By Product: Zolgensma dominated the product segment in 2025, valued at USD 1.24 billion, owing to its proven durability — with data demonstrating efficacy up to 7.5 years post-dosing for spinal muscular atrophy. Roctavian is the fastest-growing product, projected to expand at a CAGR of 38.72%.
By Vector Type: Viral vectors command an overwhelming 98.46% market share in 2026, preferred for their high transduction efficiency, targeted delivery, and long-lasting gene expression.
By Indication: Genetic disorders lead with a 31.4% share in 2025. Ophthalmology is the fastest-growing indication, expected to grow at a CAGR of 19.35%.
By End User: Hospitals & clinics hold the dominant share at 55.96% in 2026, serving as central hubs for clinical trials and ethical oversight of gene therapy programs.
North America led the market with a 24.60% share in 2025, valued at USD 1.05 billion, propelled by strong venture capital funding, robust FDA regulatory activity, and a concentration of leading biotech firms.
Europe captured the largest revenue share at 54.00% in 2025, reaching USD 2.32 billion, supported by academic research collaborations and national reimbursement initiatives.
Asia Pacific contributed approximately USD 0.4 billion (9.20% share) in 2025, with India and China emerging as notable growth pockets. Latin America and the Middle East & Africa are expected to witness moderate growth through 2034.
Prominent companies shaping the gene therapy landscape include:
Q1. What is the size and share of the global gene therapy market? The global gene therapy market was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 11.33 billion by 2034, at a CAGR of 10.20%. North America holds a 24.60% share, while Europe leads in revenue contribution at 54.00% of the global market as of 2025.
Q2. What are the key factors driving gene therapy market growth? The primary growth drivers include the rising prevalence of genetic and rare diseases globally, rapid advancements in gene delivery systems (particularly AAV vectors), increasing R&D investment and funding, and a supportive regulatory environment with growing FDA and EMA approvals.
Q3. What are the major challenges facing the gene therapy market? The two most critical challenges are the extremely high cost of therapies — limiting patient access and payer adoption — and the difficulty of maintaining long-term clinical efficacy, as transgene expression may diminish over time, necessitating extensive post-treatment monitoring and durability studies.